AZ's tozorakimab delivers COPD benefit across populations in Phase 3
AstraZeneca's anti-IL-33 antibody tozorakimab posted positive Phase 3 results in COPD (Oberon and Titania), reducing the annualized rate of moderate-to-severe exacerbations versus placebo in former smokers and showing benefit across the overall population, with a favorable safety profile. The drug’s supposed differentiation comes from complete inhibition of ST2 and RAGE/EGFR signaling, unlike rivals Roche and Sanofi/Regeneron’s IL-33 blockers that produced mixed results. AZ plans to present full data at an upcoming meeting and is pursuing two additional Phase 3 trials (Prospero, Miranda), while maintaining a target of potentially $3–5 billion in peak sales if approved.
- AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flops Fierce Biotech
- AstraZeneca drug reduces flare-ups of chronic lung disease in late-stage trials Reuters
- Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD AstraZeneca
- AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed CNBC
- AstraZeneca Shares Rise After Lung Drug Hits Goals in Late-Stage Trials WSJ
Reading Insights
0
2
2 min
vs 3 min read
82%
523 → 95 words
Want the full story? Read the original article
Read on Fierce Biotech